|
1
|
Seton-Rogers S: Lymphoma: Epigenetic
therapy gains momentum. Nat Rev Cancer. 12:7982012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Young RM and Staudt LM: Targeting
pathological B cell receptor signalling in lymphoid malignancies.
Nat Rev Drug Discov. 12:229–243. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ameres SL and Zamore PD: Diversifying
microRNA sequence and function. Nat Rev Mol Cell Biol. 14:475–488.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun K and Lai EC: Adult-specific functions
of animal microRNAs. Nat Rev Genet. 14:535–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lawrie CH: MicroRNA expression in
lymphoma. Expert Opin Biol Ther. 7:1363–1374. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang LQ, Liang R and Chim CS: Methylation
of tumor suppressor microRNAs: lessons from lymphoid malignancies.
Expert Rev Mol Diagn. 12:755–765. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lawrie CH: MicroRNAs and lymphomagenesis:
a functional review. Br J Haematol. 160:571–581. 2013. View Article : Google Scholar
|
|
8
|
Sandhu SK, Volinia S, Costinean S, et al:
miR-155 targets histone deacetylase 4 (HDAC4) and impairs
transcriptional activity of B-cell lymphoma 6 (BCL6) in the
Eμ-miR-155 transgenic mouse model. Proc Natl Acad Sci USA.
109:20047–20052. 2012. View Article : Google Scholar
|
|
9
|
Ralfkiaer U, Hagedorn PH, Bangsgaard N, et
al: Diagnostic microRNA profiling in cutaneous T-cell lymphoma
(CTCL). Blood. 118:5891–5900. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang J, Zhao L, Xing L and Chen D:
MicroRNA-204 regulates Runx2 protein expression and mesenchymal
progenitor cell differentiation. Stem Cells. 28:357–364. 2010.
|
|
11
|
Wang FE, Zhang C, Maminishkis A, et al:
MicroRNA-204/211 alters epithelial physiology. FASEB J.
24:1552–1571. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Conte I, Carrella S, Avellino R, et al:
miR-204 is required for lens and retinal development via Meis2
targeting. Proc Natl Acad Sci USA. 107:15491–15496. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Paulin R, Courboulin A, Barrier M and
Bonnet S: From oncoproteins/tumor suppressors to microRNAs, the
newest therapeutic targets for pulmonary arterial hypertension. J
Mol Med (Berl). 89:1089–1101. 2011. View Article : Google Scholar
|
|
14
|
Chung TK, Lau TS, Cheung TH, et al:
Dysregulation of microRNA-204 mediates migration and invasion of
endometrial cancer by regulating FOXC1. Int J Cancer.
130:1036–1045. 2012. View Article : Google Scholar
|
|
15
|
Sacconi A, Biagioni F, Canu V, et al:
miR-204 targets Bcl-2 expression and enhances responsiveness of
gastric cancer. Cell Death Dis. 3:e4232012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ying Z, Li Y, Wu J, et al: Loss of miR-204
expression enhances glioma migration and stem cell-like phenotype.
Cancer Res. 73:990–999. 2013. View Article : Google Scholar :
|
|
17
|
Malin S, McManus S and Busslinger M: STAT5
in B cell development and leukemia. Curr Opin Immunol. 22:168–176.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Blix ES, Irish JM, Husebekk A, et al:
Phospho-specific flow cytometry identifies aberrant signaling in
indolent B-cell lymphoma. BMC Cancer. 12:4782012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kirk R: Haematological cancer: Hit the
lymphoma, JAK. Nat Rev Clin Oncol. 9:6082012. View Article : Google Scholar : PubMed/NCBI
|
